Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy

Journal of Medical Virology

Volumn 83, Issue 3, 2011, Pages 412-418

  Sugauchi, Fuminaka ^a   Tanaka, Yasuhito ^b   Kusumoto, Shigeru ^b   Matsuura, Kentaro ^b   Sugiyama, Masaya ^b   Kurbanov, Fuat ^b   Ueda, Ryuzo ^b   Mizokami, Masashi ^c  

^a Nagoya City Koseiin Medcial Welfare Center   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

De novo; HBsAg; Hepatitis B virus; Occult infection; Reactivation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FULMINANT HEPATIC FAILURE; GENE SEQUENCE; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OCCULT HEPATITIS B; PROMOTER REGION; VIROLOGY; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA, VIRAL; FEMALE; GENOTYPE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

HEPATITIS B VIRUS;

EID: 78851471759     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21995     Document Type: Article

References (23)

1. Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, Bernaudin F, Norol F, Cordonnier C, Bobin D, Metreau JM, Vernant JP. 1998. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66: 616-619.
2. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. 1993. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 18: 1313-1318.
3. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. 1982. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447-449.
4. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. 2006. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131: 59-68.
5. Kiyosawa K, Tanaka E, Sodeyama T, Yoshizawa K, Yabu K, Furuta K, Imai H, Nakano Y, Usuda S, Uemura K., et al. 1994. Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology 106: 1596-1602.
6. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. 1992. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 103: 1649-1656.
7. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. 2009. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90: 13-23.
8. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
9. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188.
10. Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. Intervirology 46: 329-338.
11. Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, Kuramitsu T, Suzuki K, Tanaka E, Okada S, Tokita H, Asahina Y, Inoue K, Kakumu S, Okanoue T, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sakugawa H, Miyakawa Y, Ueda R, Mizokami M. 2006. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44: 326-334.
12. Sarrecchia C, Cappelli A, Aiello P. 2005. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11: 189-191.
13. Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E, Aljurf M, Gyger M. 2002. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30: 189-194.
14. Shin IT, Tanaka Y, Tateno Y, Mizokami M. 2008. Development and public release of a comprehensive hepatitis virus database. Hepatol Res 38: 234-243.
15. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. 2002. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76: 5985-5992.
16. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Gish RG, Ueda R, Miyakawa Y, Mizokami M. 2003. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124: 925-932.
17. Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. 2004a. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J Gen Virol 85: 811-820.
18. Sugauchi F, Kumada H, Sakugawa H, Komatsu M, Niitsuma H, Watanabe H, Akahane Y, Tokita H, Kato T, Tanaka Y, Orito E, Ueda R, Miyakawa Y, Mizokami M. 2004b. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 38: 1222-1228.
19. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. 2006. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44: 915-924.
20. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M. 2009. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 136: 652-662 e653.
21. Tanaka Y, Orito E, Yuen MF, Mukaide M, Sugauchi F, Ito K, Ozasa A, Sakamoto T, Kurbanov F, Lai CL, Mizokami M. 2005. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Hepatol Res 33: 216-224.
22. Umemura T, Tanaka E, Kiyosawa K, Kumada H. 2008. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47: e52-56.
23. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27: 605-611.